LAMA2 France supports two new research projects with funding

The French patient association LAMA2 France, dedicated to people affected by LAMA2-related dystrophy (LAMA2-RD), is pleased to announce that they will be supporting two new research projects this year, dedicated to understanding and developing treatments for congenital muscular dystrophy linked to the LAMA2 gene, for a total amount of nearly €50.000.

LAMA2 France explains: ,,This funding is part of our ongoing commitment to accelerating therapeutic research and promoting collaboration between scientific teams in France, Europe and internationally. We received eight applications for this second call for projects. Following evaluations conducted by the Rare Diseases Foundation and recommendations from our Scientific Advisory Board, we decided to fund two of them. These two projects were selected on the basis of their scientific excellence, their potential clinical impact, and their complementarity with research efforts already underway.”

• The first project is entitled ‘Regulation of MYMK and MYMX fusogens to characterise their role in the pathogenesis of LAMA2-related congenital muscular dystrophy’. It is led by Dr Previtali of the Università Vita-Salute San Raffaele.
• The second project, entitled ‘Spatial Transcriptomics in Paediatric Human LAMA2 Skeletal Muscle’, focuses on the spatial transcriptomics of muscle cells in children with LAMA2 dystrophy. It is coordinated by Dr Przytycki and his team at Boston University, with Dr. Julien Moy as part of the team.